Rui Tang

Rui Tang

Auto-generated profile, based on publicly available information

Rui Tang

Washington University in St. Louis

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Cancer Discovery
Verified
Journal Article
Closed access
CMChristopher W. Murray
Christopher W. Murray
JBJennifer J. Brady
Jennifer J. Brady
MTMin K. Tsai
Min K. Tsai
CLChuan Li
Chuan Li
IWIan P. Winters
Ian P. Winters
MWMonte M. Winslow
Monte M. Winslow
The kinase LKB1 is a critical tumor suppressor in sporadic and familial human cancers, yet the mechanisms by which it suppresses tumor growth remain poorly understood. To investigate the tumor-suppressive capacity of four canonical families of LKB1 substrates in vivo, we used CRISPR/Cas9-mediated combinatorial genome editing in a mouse model of oncogenic KRAS-driven lung adenocarcinoma. We demonstrate that members of the SIK family are critical for constraining tumor development. Histologic and gene-expression similarities between LKB1- and SIK-deficient tumors suggest that SIKs and LKB1 operate within the same axis. Furthermore, a gene-expression signature reflecting SIK deficiency is enriched in LKB1-mutant human lung adenocarcinomas and is regulated by LKB1 in human cancer cell lines. Together, these findings reveal a key LKB1–SIK tumor-suppressive axis and underscore the need to redirect efforts to elucidate the mechanisms through which LKB1 mediates tumor suppression. Significance: Uncovering the effectors of frequently altered tumor suppressor genes is critical for understanding the fundamental driving forces of cancer growth. Our identification of the SIK family of kinases as effectors of LKB1-mediated tumor suppression will refocus future mechanistic studies and may lead to new avenues for genotype-specific therapeutic interventions. This article is highlighted in the In This Issue feature, p. 1469

19 February 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
HCHongchen Cai
Hongchen Cai
SCSu Kit Chew
Su Kit Chew
CLChuan Li
Chuan Li
MTMin K. Tsai
Min K. Tsai
LALaura Andrejka
Laura Andrejka
MWMonte M. Winslow
Monte M. Winslow
Cancer genotyping has identified a large number of putative tumor suppressor genes. Carcinogenesis is a multistep process, but the importance and specific roles of many of these genes during tumor initiation, growth, and progression remain unknown. Here we use a multiplexed mouse model of oncogenic KRAS–driven lung cancer to quantify the impact of 48 known and putative tumor suppressor genes on diverse aspects of carcinogenesis at an unprecedented scale and resolution. We uncover many previously understudied functional tumor suppressors that constrain cancer in vivo. Inactivation of some genes substantially increased growth, whereas the inactivation of others increases tumor initiation and/or the emergence of exceptionally large tumors. These functional in vivo analyses revealed an unexpectedly complex landscape of tumor suppression that has implications for understanding cancer evolution, interpreting clinical cancer genome sequencing data, and directing approaches to limit tumor initiation and progression.Significance: Our high-throughput and high-resolution analysis of tumor suppression uncovered novel genetic determinants of oncogenic KRAS–driven lung cancer initiation, overall growth, and exceptional growth. This taxonomy is consistent with changing constraints during the life history of cancer and highlights the value of quantitative in vivo genetic analyses in autochthonous cancer models.This article is highlighted in the In This Issue feature, p. 1601

7 October 2020 in eLife
Verified
Journal Article
Open access
RTRui Tang
Rui Tang
CMChristopher W Murray
Christopher W Murray
ILIan L Linde
Ian L Linde
NKNicholas J Kramer
Nicholas J Kramer
ZLZhonglin Lyu
Zhonglin Lyu
MWMonte M Winslow
Monte M Winslow
Cell-cell interactions influence all aspects of development, homeostasis, and disease. In cancer, interactions between cancer cells and stromal cells play a major role in nearly every step of carcinogenesis. Thus, the ability to record cell-cell interactions would facilitate mechanistic delineation of the role of the cancer microenvironment. Here, we describe GFP-based Touching Nexus (G-baToN) which relies upon nanobody-directed fluorescent protein transfer to enable sensitive and specific labeling of cells after cell-cell interactions. G-baToN is a generalizable system that enables physical contact-based labeling between various human and mouse cell types, including endothelial cell-pericyte, neuron-astrocyte, and diverse cancer-stromal cell pairs. A suite of orthogonal baToN tools enables reciprocal cell-cell labeling, interaction-dependent cargo transfer, and the identification of higher order cell-cell interactions across a wide range of cell types. The ability to track physically interacting cells with these simple and sensitive systems will greatly accelerate our understanding of the outputs of cell-cell interactions in cancer as well as across many biological processes.

20 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DHDavid S. Hong
David S. Hong
PLPatricia LoRusso
Patricia LoRusso
OHOmid Hamid
Omid Hamid
DBDarrin M. Beaupre
Darrin M. Beaupre
FJFilip Janku
Filip Janku
EKEunice Lee Kwak
Eunice Lee Kwak
2508 Background: Dysregulation of the MET pathway can promote tumor growth and metastasis, making MET an attractive target for cancer therapy. AMG 337 is an investigational, oral inhibitor of MET kinase activity. This study evaluated the safety, tolerability, pharmacokinetics, and efficacy of AMG 337. Methods: Key eligibility: age ≥ 18 years, advanced solid tumors, measurable disease, ECOG ≤ 2, adequate organ function. AMG 337 was administered orally QD or BID on D1 and D3–28. After 1 week without AMG 337 in the absence of dose-limiting toxicity (DLT) or progression, pts resumed AMG 337 until progression. The starting dose of AMG 337 was 25 mg with planned dose escalation of 50-500 mg QD and 100-200 mg BID (3-9 pts/cohort) until the maximum tolerated dose (MTD, highest dose at which < 33% of pts/cohort had a DLT) was reached or the highest dose was tested. Pts with MET overexpression/amplification/mutation could enroll to the highest dose deemed safe at any time. Results: As of OCT 2013, 66 pts (QD escala...

23 June 2025 in Nature Chemical Biology
Verified
Journal Article
Closed access
QNQiuyue Nie
Qiuyue Nie
FZFanglong Zhao
Fanglong Zhao
XYXuerong Yu
Xuerong Yu
MMMithun C. Madhusudhanan
Mithun C. Madhusudhanan
CCCaleb Chang
Caleb Chang
XGXue Gao
Xue Gao

30 May 2025 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
JHJess D. Hebert
Jess D. Hebert
HXHaiqing Xu
Haiqing Xu
YTYuning J. Tang
Yuning J. Tang
PRPaloma A. Ruiz
Paloma A. Ruiz
CDColin R. Detrick
Colin R. Detrick
MWMonte M. Winslow
Monte M. Winslow